ID: ALA429291

Max Phase: Preclinical

Molecular Formula: C23H23N3O2

Molecular Weight: 373.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCN(CC)CCC(=O)Nc1ccc2c(c1)C(=O)c1cccc3ccnc-2c13

Standard InChI:  InChI=1S/C23H23N3O2/c1-3-26(4-2)13-11-20(27)25-16-8-9-17-19(14-16)23(28)18-7-5-6-15-10-12-24-22(17)21(15)18/h5-10,12,14H,3-4,11,13H2,1-2H3,(H,25,27)

Standard InChI Key:  PHJCUOIBBDUYDG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 373.46

Molecular Weight (Monoisotopic): 373.1790

AlogP: 4.12

#Rotatable Bonds: 6

Polar Surface Area: 62.30

Molecular Species: BASE

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.59

CX Basic pKa: 9.00

CX LogP: 3.34

CX LogD: 1.74

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.55

Np Likeness Score: -0.75

References

1. Tang H, Ning FX, Wei YB, Huang SL, Huang ZS, Chan AS, Gu LQ..  (2007)  Derivatives of oxoisoaporphine alkaloids: a novel class of selective acetylcholinesterase inhibitors.,  17  (13): [PMID:17451950] [10.1016/j.bmcl.2007.04.015]

2. Tang H, Wang XD, Wei YB, Huang SL, Huang ZS, Tan JH, An LK, Wu JY, Chan AS, Gu LQ..  (2008)  Oxoisoaporphine alkaloid derivatives: synthesis, DNA binding affinity and cytotoxicity.,  43  (5): [PMID:17720282] [10.1016/j.ejmech.2007.07.004]

3. Li YP, Ning FX, Yang MB, Li YC, Nie MH, Ou TM, Tan JH, Huang SL, Li D, Gu LQ, Huang ZS..  (2011)  Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation.,  46  (5): [PMID:21367493] [10.1016/j.ejmech.2011.02.005]

Source

Source(1):

• Scientific Literature